targeted therapy

ASCO ® American Society of Clinical Oncology; Clinical Cancer Advances 2019: ASCO's Annual Report on Progress Against Cancer
January 31, 2019
Greg Guthrie, ASCO Staff

Progress in Treating Rare Cancers: The 2019 Advance of the Year

English
Greg Guthrie

In 2019, ASCO recognizes the progress in treating rare cancers as the Advance of the Year. Impressive progress has been made in bringing new treatment advances to cancers that are rare and difficult to treat. This year’s Clinical Cancer Advances report describes emerging treatments for thyroid cancer, uterine cancer, desmoid tumor, neuroendocrine tumor, and tenosynovial giant cell tumor.

Read More >>
December 20, 2018
Richard L. Schilsky, MD, FACP, FSCT, FASCO

Tumor-Agnostic Treatment for Cancer: An Expert Perspective

English
Richard.Schilsky

Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.

Read More >>
February 14, 2018
Greg Guthrie, ASCO staff

Biosimilars and Cancer Care: An Expert Opinion

English
gregguthrie

In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.

Read More >>
July 19, 2016

TAPUR: Looking for Answers in Targeted Therapy

English

The Targeted Agent and Profiling Utilization Registry (TAPUR) study is ASCO’s first clinical trial. In this podcast, ASCO Chief Medical Officer Dr. Richard Schilsky discusses TAPUR and why it is important to patients and the medical community.

Read More >>

Pages

Subscribe to RSS - targeted therapy